Tumor Mutational Burden (TMB)

The fundamental premise of TMB as a biomarker is that a higher number of somatic mutations leads to the production of more neoantigens—abnormal proteins recognized as foreign by the immune system. A high TMB increases the probability that at least one neoantigen will be effectively presented by Major Histocompatibility Complex (MHC) molecules, priming a T-cell-mediated anti-tumor response. This is the mechanistic basis for the success of immune checkpoint inhibitors (ICIs) in high-TMB tumors.

TMB is measured in mutations per megabase (mut/Mb). The calculation involves sequencing tumor and matched normal DNA to filter out germline variants, then counting somatic, non-synonymous single nucleotide variants and small insertions/deletions within the targeted coding region. Standardization is a critical challenge:

• Panel Size: Whole Exome Sequencing (WES) is the gold standard, but targeted gene panels (e.g., MSK-IMPACT, FoundationOne CDx) require rigorous calibration and bioinformatic correction.
• Cutoff Variability: A universal 'high TMB' threshold does not exist; it varies by cancer type, panel used, and clinical trial design, though ≥10 mut/Mb is a common reference point.

In 2020, the FDA granted a tissue-agnostic approval for pembrolizumab in patients with unresectable or metastatic solid tumors exhibiting a high TMB (≥10 mut/Mb), as determined by an FDA-approved test. This landmark decision established TMB as a pan-cancer biomarker, meaning its predictive value is not confined to a single tumor histology. This status is rare and places TMB alongside only a few other biomarkers like Microsatellite Instability (MSI) and NTRK fusions.

A transformative characteristic of TMB is its predictability from digitized H&E-stained whole slide images using deep learning. Models based on Multiple Instance Learning (MIL) and Vision Transformers (ViTs) can infer a tumor's genomic instability from its morphological phenotype alone. This bypasses the need for costly and time-consuming sequencing, offering a rapid, scalable screening tool. Key morphological correlates include:

• Tumor-Infiltrating Lymphocyte (TIL) density and spatial patterns
• Nuclear pleomorphism and chromatin texture
• Stromal architecture and tumor budding

TMB is an imperfect predictor of immunotherapy response due to several biological and technical confounders:

• Neoantigen Quality over Quantity: Not all mutations create immunogenic neoantigens. The clonality and MHC binding affinity of the resulting peptides are critical qualitative factors TMB ignores.
• Intratumoral Heterogeneity: A single biopsy may not represent the mutational landscape of the entire tumor, leading to sampling bias.
• Indeterminate Cases: A significant fraction of patients with low TMB still respond to ICIs, and vice versa, indicating that TMB must be interpreted alongside other biomarkers like PD-L1 expression and MSI status.

The highest clinical utility for TMB is achieved not in isolation, but through multi-modal diagnostic fusion. Integrating TMB scores with complementary data streams creates a holistic patient profile:

• Radiomics: Quantitative features from CT/MRI scans correlate with tumor heterogeneity and TMB status.
• Transcriptomics: Gene expression signatures of immune activation (e.g., interferon-gamma pathway) refine the prediction of ICI response.
• Pathomics: Deep learning features extracted from H&E slides provide spatial context to the mutational count. This fusion approach addresses the limitations of TMB as a single-analyte biomarker, moving toward a more robust, integrated prediction of therapeutic benefit.